Over the two-year study period, patients receiving GLP-1based therapy experienced: Importantly, the study authors did not observe an increased risk for key diabetes-related complications, including diabetic ketoacidosis and hypoglycemia
Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L
77-80 The numerous ongoing clinical trials and research studies will help further elucidate their benefits in other disease settings
Cattaneo M, Franchi F, Zighetti ML, Maritnelli I, Asti D, and Mannucci PM (1998)
Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44
